Search
Tarsus Pharmaceuticals Inc
TARSAdd to Watchlist
72.080USD
+1.580+2.24%
Close 10-22 16:00（ET）
3.10BMarket Cap
LossP/E TTM
Tarsus Pharmaceuticals Inc (TARS) Stock Price Target & Forecast
Analyst Rating
Based on 10 analysts giving stock ratings to Tarsus Pharmaceuticals Inc in the past month.
Strong Buy
5 Strong Buy
5 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
99.556USD+46.25%
TARS Analyst Recommendation Trends
In the current month, TARS has received 5 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TARS average Analyst price target in the last month is 99.556.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
5
5
5
5
5
5
5
5
5
5
4
4
4
4
4
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10
10
9
9
9
9
9
9
TARS Analyst Rating for Peer Comparison
Updated: Oct 20, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
9
17
11
1
0
38
Amgen Inc
AMGN
4
9
19
3
1
36
AbbVie Inc
ABBV
8
19
6
0
0
33
Vertex Pharmaceuticals Inc
VRTX
10
17
5
0
1
33
Eli Lilly and Co
LLY
10
19
3
1
0
33
Alnylam Pharmaceuticals Inc
ALNY
7
17
8
0
0
32
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Merck & Co Inc
MRK
7
16
8
0
0
31
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Regeneron Pharmaceuticals Inc
REGN
7
15
9
0
0
31
Financial Forecasting
Based on analysts' estimates, TARS EPS is projected to reach -1.554 in FY2026Q3, following reported EPS of -0.428 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.10
-0.37
-0.20
-1.55
-0.12
Actual
-0.20
-0.16
-0.43
--
--
Surprise
-105.79%
+56.22%
-118.12%
--
--
FAQs
What is Tarsus Pharmaceuticals Inc's expected revenue for the next quarter?
Tarsus Pharmaceuticals Inc's expected revenue is 184.76M.
What is Tarsus Pharmaceuticals Inc's price target?
Analysts forecast that Tarsus Pharmaceuticals Inc's price target is USD 99.56, with the highest forecast at USD 116.00 and the lowest forecast at USD 84.00.
How have Tarsus Pharmaceuticals IncTARS's recent earnings per share performed?
The market expectation was USD -0.43, while Tarsus Pharmaceuticals IncTARS's earnings per share (EPS) for the previous quarter was USD -0.16. EPS for the next quarter is expected at USD -1.55.
What is the analyst rating for Tarsus Pharmaceuticals Inc?
Based on the ratings of Tarsus Pharmaceuticals Inc's stock from 10 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.